Published in Oncotarget on October 09, 2016
Genome Wide Association Studies of Chemotherapeutic Toxicities: Genomics of Inequality. Clin Cancer Res (2017) 0.75
A method and server for predicting damaging missense mutations. Nat Methods (2010) 78.53
Predicting deleterious amino acid substitutions. Genome Res (2001) 28.95
Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science (2012) 17.12
A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet (2014) 14.56
An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. Science (2012) 7.94
Why are African Americans under-represented in medical research studies? Impediments to participation. Ethn Health (1997) 4.63
Representation of American blacks in clinical trials of new drugs. JAMA (1989) 2.86
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol (2014) 2.57
Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel. Clin Cancer Res (2014) 2.25
Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. J Clin Oncol (2012) 1.85
Genome-wide insights into the patterns and determinants of fine-scale population structure in humans. Am J Hum Genet (2009) 1.64
A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res (2012) 1.50
Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin (2014) 1.36
CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res Treat (2012) 1.23
A genome-wide association study of alcohol-dependence symptom counts in extended pedigrees identifies C15orf53. Mol Psychiatry (2012) 1.21
Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat (2010) 1.19
A systematic review of taxane-containing regimens for metastatic breast cancer. Br J Cancer (2005) 1.15
Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221). Breast Cancer Res Treat (2011) 1.10
Sequencing of Charcot-Marie-Tooth disease genes in a toxic polyneuropathy. Ann Neurol (2014) 1.06
Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy. J Med Genet (2013) 1.03
Regulatory polymorphisms in β-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy. Clin Cancer Res (2012) 1.03
Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199. Clin Cancer Res (2015) 0.98
Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy. Clin Cancer Res (2014) 0.94
SNPs and taxane toxicity in breast cancer patients. Pharmacogenomics (2014) 0.91
Charcot-Marie-Tooth diseases: an update and some new proposals for the classification. J Med Genet (2015) 0.85
Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. Br J Cancer (2014) 0.84
Symptoms: Chemotherapy-Induced Peripheral Neuropathy. Adv Exp Med Biol (2015) 0.81
The administration of chemotherapy in a patient with Charcot-Marie-Tooth and ovarian cancer. Gynecol Oncol (2005) 0.80